New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Nasus Pharma, Ltd.

Contributing Author

Recent Articles by Nasus Pharma, Ltd.

Mar-25	Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update NSRX +10.84% GlobeNewswire
Mar-16	Nasus Pharma Announces Positive Top Line Data from Phase 2 Clinical Study of NS002: Achieves Significantly Superior and Faster Epinephrine Delivery Compared to EpiPen with Accelerated Speed to Therapeutic Threshold NSRX -38.00% GlobeNewswire
Mar-09	Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study NSRX -15.43% GlobeNewswire
Mar-09	Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum NSRX -15.43% GlobeNewswire
Feb-20	Nasus Pharma to Participate in Upcoming Investor Conferences NSRX +18.00% GlobeNewswire
Feb-17	Nasus Pharma to Present Data Highlighting Superior Nasal Deposition and Stability of Intranasal Epinephrine Powder at AAAAI 2026 NSRX GlobeNewswire
Feb-13	Nasus Pharma Announces Closing of $15.0 Million Private Placement NSRX +5.36% GlobeNewswire
Feb-10	Nasus Pharma Announces Pricing of $15.0 Million Private Placement NSRX GlobeNewswire
Jan-20	Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder NSRX -7.52% GlobeNewswire
Dec-22	Nasus Pharma CEO Issues 2025 Letter to Shareholders NSRX -6.56% GlobeNewswire
Nov-20	Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer NSRX GlobeNewswire
Nov-18	Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed NSRX GlobeNewswire
Nov-06	Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder NSRX GlobeNewswire
Sep-02	Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference NSRX GlobeNewswire
Aug-26	Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony NSRX GlobeNewswire
Aug-14	Nasus Pharma Announces Closing of Initial Public Offering NSRX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)